title: Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease.
abstract: Treatment of 66 hypertensive patients with three different beta-blockers (atenolol 100 mg once a day; oxprenolol 80 mg twice a day; nadolol 80 mg once a day) for six months resulted in a significant reduction in blood pressure and heart rate, the maximum with nadolol, a significant amelioration in pre-ejection period/left ventricular ejection time ratio expressing the haemodynamic performance of the left ventricle with atenolol and nadolol, and a significant reduction left ventricular hypertrophy as expressed by the Romhilt-Estes index with all three drugs, but especially with nadolol.
authors.forename: F
authors.initials: F
authors.lastname: Pupita
authors.forename: R
authors.initials: R
authors.lastname: Ansuini
authors.forename: M
authors.initials: M
authors.lastname: Belogi
authors.forename: G
authors.initials: G
authors.lastname: Pupita
authors.forename: S
authors.initials: S
authors.lastname: Gaggi
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy* / Q000209:etiology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D010096:Oxprenolol / Q000009:adverse effects / Q000627:therapeutic use; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk
chemical_list: D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D009248:Nadolol; D001262:Atenolol; D010096:Oxprenolol